Orthopediatrics Corp ( (KIDS) ) has released its Q4 earnings. Here is a breakdown of the information Orthopediatrics Corp presented to its investors.
OrthoPediatrics Corp. is a specialized orthopedic company dedicated to advancing pediatric orthopedics, offering a comprehensive range of products to improve the lives of children with orthopedic conditions globally.
In its latest financial report, OrthoPediatrics Corp. announced a record full-year revenue of $204.7 million for 2024, marking a 38% increase from the previous year, alongside a significant rise in adjusted EBITDA. The company also highlighted its success in helping a record number of children and reiterated its revenue guidance for 2025.
Key financial metrics from the report include a 40% increase in fourth-quarter revenue to $52.7 million, driven by strong domestic growth and contributions from the acquisition of Boston O&P. The company’s adjusted EBITDA for the fourth quarter more than doubled to $3.0 million. Despite these gains, OrthoPediatrics reported a net loss of $16.1 million for the quarter, attributed to increased operating expenses and restructuring charges.
The company also noted a reduction in free cash flow usage and anticipates achieving positive free cash flow by the fourth quarter of 2025. Looking ahead, OrthoPediatrics expects to continue its growth trajectory with projected revenue increases of 15% to 18% in 2025, supported by strategic expansions and product offerings.
OrthoPediatrics remains optimistic about its future, with management expressing confidence in further building on past successes and achieving long-term goals, including helping one million children annually. The company is poised to capture more market share and drive growth across its diverse business segments.